CGON earnings analysis
What we found in CGON's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
CG Oncology reported Q1 2026 total revenue of $1.08 million, exceeding estimates by $0.08 million. However, the company reported a net loss of $60.2 million or $(0.71) per share, missing estimates by $0.26. The cash position has strengthened significantly to approximately $1.1 billion.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Revenue Exceeds Estimates
- Actual revenue was $1.083 million, exceeding estimates of $0.512 million by 112%.
- Significant Operating Loss
- Net loss increased to $60.2 million from $34.5 million year-over-year.
- Strong Cash Position
- Cash and cash equivalents reached $1,076.2 million as of March 31, 2026.
- Increased R&D Expenses
- R&D expenses rose to $43.7 million, up from $27.5 million in the previous year.
- Commercial and Development Revenue
- Commercial and development revenue was $1.069 million, compared to zero in the prior period.
- Cash Flow from Financing
- Net cash provided by financing activities was $392.998 million, largely from equity offerings.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Rising Net Losses
- The net loss increased by $25.75 million compared to the same quarter last year.
- High Cash Burn Rate
- Cash used in operating activities was $56.9 million, up from $29.3 million year-over-year.
- Regulatory and Development Risks
- The ability to commercialize cretostimogene is uncertain and may delay future revenues.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-0.71
What they said about what is next.
Outlook deferred to earnings press release / call.
The filing reads about the same as the one before it.
What came before.
- 10-K · February 27, 2026
- CG Oncology is a late-stage biotech centered on a single product candidate, cretostimogene, with a BLA submission initiated in the fourth quarter of 2025 that the company "expect[s] to complete in 2026." The filing…
- 10-Q · August 8, 2025
- CG Oncology reported Q2 2025 results showing zero license & collaboration revenue and a wider net loss as operating spend stepped up. Quarterly net loss was $41,426 (EPS -$0.54) driven by higher R&D ($31,331) and G&A…
- 10-Q · May 13, 2025
- CG Oncology reported Q1 2025 operating results showing stepped-up R&D investment and a wider loss while maintaining a sizable liquidity position. Revenue (license & collaboration) was $52,000 and net loss was $34.5…
- 10-K · March 28, 2025
- Crogen (CGON) is a late-stage clinical biotech focused on cretostimogene grenadenorepvec for bladder cancer; Phase 3 BOND-003 Cohort C topline data show a 75.5% complete response (CR) rate at any time and median…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing CGON makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever